Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMG 732

Next Previous
Drug Profile

AMG 732

Alternative Names: AMG-732; HZN 280

Latest Information Update: 15 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Graves ophthalmopathy

Most Recent Events

  • 09 Jun 2026 Phase-II clinical trials in Graves ophthalmopathy in Spain (SC) (CTIS2025-523280-38-00)
  • 07 May 2026 Phase-II clinical trials in Graves ophthalmopathy in United Kingdom (SC)(NCT07438405)
  • 25 Feb 2026 Amgen plans a phase II HAZEL 401 trial for Graves ophthalmopathy in February 2026 (SC) (NCT07438405)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top